NCT04990726View on ClinicalTrials.gov

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Active, not recruitingOBSERVATIONAL

Enrollment

126

Participants

Timeline

Start Date

December 5, 2019

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8Melanoma, Stage IIMelanoma Stage IV

Interventions

BEHAVIORAL

Assessment

Undergo medical assessments

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Complete questionnaires

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT04990726 - Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter